Your peps might be okay—several other factors could be at play.
Without additional details, it’s tough to tell.
Have you maintained a calorie deficit?
Have you tried increasing your activity?
Frequently, when individuals "diet," it amplifies food noise—thoughts about eating.
Reta can assist by slowing digestion, but it provides less satiety than Tirz, for instance.
Perhaps you received a poor batch—did you arrange any testing? (do not mention source of peps)
Perhaps you are a non-responder:
NCBI research characterizes GLP-1 non-responders as those who shed under 5% of body weight or miss targeted glycemic thresholds (e.g., in type 2 diabetes) following 3 to 6 months of treatment. Studies indicate that 9% to 27% of patients might fit this group, although genuine non-responsiveness is typically uncommon. [
1,
2,
3,
4,
5]
Main causes of diminished effectiveness or non-response recorded in National Center for Biotechnology Information (NCBI) | (.gov) literature encompass:
- Genetic Factors: Alterations in the GLP-1 receptor gene (GLP1R) or other genes tied to obesity pathways may weaken the drug's impact. [1, 2]
- Metabolic & Health Status: Individuals with elevated baseline insulin resistance, existing impaired glucose regulation, or particular concurrent thyroid conditions might see reduced weight loss. [1, 2]
- Medication & Dosing: Stopping early before hitting the maximum therapeutic dose, or concurrently using medications that cause weight gain, can lead to inadequate responses. [1, 2]
NCBI reviews—such as a study reachable through
PubMed Central (PMC)—recommend that physicians assess these pharmacological, clinical, and genetic obstacles prior to changing a treatment plan. Clinical options frequently include dose modifications, transitioning to more potent drugs, or pairing therapies with lifestyle changes or weight-loss surgery
